| ID | 10257 |
| Vaccine Name | Vidprevtyn |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Protein subunit |
| Vaccine Status | Phase 2 |
| Manufacturer | Sanofi Pasteur, GlaxoSmithKline |
| Year of Manufacturing | NA |
| Manufacturing Country | NA |
| Age | NA |
| Dosage | 2 doses 21 days apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | Spike protein of SARS-CoV-2 virus |
| Description | Baculovirus production |
| Approving Organisation | NA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | VAT00002, VAT00008, SARS-CoV-2 vaccine |
| PMID | 33816047 |
| Clinical Trial ID | NA |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ |
| Additional Links | NA
|